2/1/16 6/11/01 SHEET 1 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. NIH061.1CP1C2	APPLICATION NOunknown- 09/756,411
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
	Lori et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE herewith	GROUP Art Unit
	Helewiai	1623

	U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)			
**	-1	4,708,818	11/24/87	Montagnier et al.						
**	-2	5;026;687	06/25/91	Yarchoan et al.						
/*/	-3	5,110,600	05/05/92	Green						
**	-4	5,300,059	04/05/94	Rubinstein et al.						
**	-5	6,046,175	04/04/00	Lori et al.						
**	6	6,093,702	07/25/00-	Malley, et-al-						
**	- 7	5,521,161	05/28/06	Malley et al.			-			
**	8	5,736,526	04/07/98	Malley et al.						
**-	9	5,736,527	04/07/99	Malley et al.						

	FOREIGN PATENT DOCUMENTS											
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	TRANSLATION				
INITIAL							YES	NO				
[**	-10	EP 0 206-497	12/30/86	EPO								
**	-11	WO 87/01284	03/12/87	WIPO								
Ske	12	WO 92/08699	05/29/92	WIPO			•					
gre	13	WO 93/12782	07/08/93	WIPO			,					
Me	14	WO 93/23368	11/25/93	WIPO			-					
me	15	WO 94/27590	12/08/94	WIPO	_							
The	16	WO 95/17899	07/06/95	WIPO								

^{**} Duplicate of reference alredy of record on a PTO-892.

		<u> </u>	<u>z </u>					
EXAMINER	N	7	C	an I.	E.	Crane	DATE CONSIDERED	06/12/01

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. NIH061.1CP1C2 APPLICATION NO.

unknown- 09/756,411

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT Lori et al.

FILING DATE herewith

Art Unit 1623 GROUP

~unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
01	17	Albert et al., Experimental Cell Research, 179: 417-428, 1988,						
The	!	"Deoxyadensoine Toxicity and Cell Cycle Arrest in Hydroxyurea-Resistant S49 T-Lymphoma Cells."						
Pres	18	Altman, L.K., New York Times, p. 38, Sunday, September 17, 1995,						
THE		"Study Challenges AZT Role as the Chief Drug for H.I.V."						
and	19	Balzarini et al., Molecular Pharmacology, 32: 798-806, 1987,						
ype	!	"2', 3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis."						
**	-20	Barre Sinoussi et al., Science, 220: 868-871, 1983,						
		"Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)."						
ara.	21	Biron et al., Journal of Acquired Immune Deficiency Syntromes and Human Retrovirology, 10(1): 36-40, 1995,						
400	_!	"Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals."						
**	_22	Bukrinsky et al., Science, 254: 233-237, 1991,						
		"Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection."						
-**	-23	Busso et al., AIDS-Res. Human-Retroviruses, 6(9): 1139-1148, 1990,						
		"Cellular Pharmacology and Anti-HIV Activity of 2', 3'-Dideoxyguanosine."						
**	-24	Genters for Disease Control, Morbidity Mortality Weekly Report, 30(25): 305-308, July 3, 1981,						
		"Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men."						
**-	25	Chow et al., Nature, 361: 650-654, 1993,						
		"Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy."						
Que !	26	Coffin, H., Fundamental Virology 2nd Edition, pp. 545-708, Raven Press, New York, 1991,						
gu	!	"Retroviridae and Their Replication."						
**	27	Fauci, Science, 239: 617-622, 1988,						
		"The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis."						
**	-28	Fauci, Science, 262: 1011-1018, 1993,						
		"Multifactoral Nature of Human Immundeficiency Virus Disease: Implications for Therapy."						
**-	-29	Feorino et al., Antiviral Chemistry & Chemotherapy, 4(1): 55-63, 1993,						
		"Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells."						
01	30	Fischl, AIDS Clin. Rev., 94: 167-187, 1993,						
gres	1	Treatment of HIV Disease in 1993/1994."						
	**	Duplicate of reference already cited on a PTO-892.						
	1	Month of publication data is unavailable for this reference.						
XAMINER	_6	M Cur L. E. Crane DATE CONSIDERED 06/12/01						

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. NIH061.1CP1C2	APPLICATION NO. 09/756,411
	DISCLOSURE STATEMENT APPLICANT	APPLICANT Lori et al.	
(USE SEVERAL	. SHEETS IF NECESSARY)	FILING DATE herewith	GROUP Art Unit 1623

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
**	-31-	Fox et al., <i>J. Infectious Diseases</i> , 164: 1051-1057, 1991,
		"Lymphoid Germinal Centers are Resevoirs of Human Immunodeficiency."
Q,	32	Gao, Aids Research and Human Viruses, 10(1): Supp. 3, Abstract No. 355, 1994,
gre	!	"Mechanisms of the Enhanced Anti-HIV-1 Activities of 2', 3'-Dideoxynucleoside Analogs by Hydroxyurea."
0,	33	Gao et al., Clnical Research, 42(2): 280A, 1994,
Me	-!	"Anti-HIV-1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
20	34	Gao et al., Mol. Pharmacol., 46(4): 767-772, 1994,
MU	1	"Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides."
-**-	_35	Gao-et-al., Proc. Natl. Acad. Sci. USA, 90, 8925-8928, October 1993,
		"Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication."
aca	36	Goulaiouic et al., C.R. Acad. Sci. Paris, 317: 430-436, 1994,
gol	!	"Potentiation of 2', 3'-Dideoxycytidine (ddc) by Hydroxyurea and Thymidine on the Moloney Murine Leukemia Virus (MoMLV) Early Replicative Steps."
1.1	37 !	Goulaouic et al., <i>Virology</i> , 200: 87-97, 1994,
me		"Exogenous Nucleosides Promote the Completionof MoMLV DNA Synthesis in GO-Arrested Balb c/3t3 Fibroblasts."
1	38	Hao et al., Molecular Pharmacology, 34:431-435, 1988,
The	!	"Factors Determining the Activity of 2', 3'-Dideoxynucleosides in Supressing Human Immunodeficiency Virus In Vitro."
	39	Hirsch et al., N. Engl. J. Medicine, 328(23): 1686-1695, 1993,
		"Therapy for Human Immunodeficiency Virus Infection."
Oppo	40	Huber et al., <i>J. of Biological Chemistry</i> , 264(8): 4669-4678, 1989,
yja	[!	"Human Immunodeficiency Virus I Reverse Transcriptase."
040	41	Hubscher, H., Experientia, 39(1): 1-25, 1983,
Me	!	"DNA Polymerases in Prokaryotes and Eukaryotes: Mode of Action and Biological Implications."
6	42	Ji et al., Mol. Gen. Genet., 226: 257-264, 1991,
Mre	١,	"Analysis of Mutagenesis Induced by a Thermolabile T4 Phage Deoxycytidylate Hydroxymethylase Suggests Localized Deoxyribonucleotide Pool Imbalance."
**	43	Karlsson et al., <i>Eur. J. Biochem</i> , 186: 689-694, 1989,
		"Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells."
Q.	44	Kati et al., J. of Biological Chemistry, 267(36): 25988-25997, 1992,
July	!	"Mechanism and Fidelity of HIV Reverse Transcriptase."
**]	Dup1	icate of reference already of record on a PTO-892.

-								
EXAMINER	La L. E. Crane	DATE CONSIDERED	06/12/01					
*EXAMINER: INITIAL # CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.								
	! Month of publication data is unav	vailable for the	is reference.					

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. NIH061.1CP1C2

09/756,411

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT Lori et al.

FILING DATE herewith

GROUP Art Unlit 1603

-unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	45	Langreth, The Wall Street Journal, p. B12, November 21, 1995,						
Me		"FDA Gives Approval to Glaxo, Sequus to Market Separate AIDS Therapies."						
**	46	Licastro-et-al. , Biochem. Biophys. Res. Comm., 132(3): 929-933, 1985,						
**		"Inhibition of Polymerases- α and - β Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells."						
Pro	47	Lien, Progress in Drug Research, 31: 101-126, 1987,						
910	. !	"Ribonucleotide reductase inhibitors as anticancer and antiviral agents."						
1	48	Lori et al., Antiviral Res., Vol. 23, Supp. 1, page 63, 1994,						
ne	1	"Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1."						
Phra	49	Lori et al., J. of Virol., 66(8): 5067-5074, 1992,						
//w	-!	"Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions."						
11	50	Lori et al., International Conference on Aids, 10(1): 8, Abstract No. 007b, 1994						
yu	!	"Hydroxyurea as a Novel Potent Inhibitor of HIV-1 Replication."						
**	-51	Lori et al., Science, 266(5186): 801-805, 1994,						
		"Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus Type 1 Replication."						
0	52	Malley et al., The Lancet, 343(8908): 1292, 1994,						
Mec	!	"Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds."						
1	53	Malley, Proc. Nat. Acad. Sci. USA, 91(23): 11017-11021, November 1994,						
me		"Synergistic Anti-Human Immunodeficiency Virus Type 1 Effect of Hydroxamate Compounds with 2', 3'- Dideoxyinosine in Infected Resting Human Lymphocytes."						
**	-54	Marquez et al., <i>J. Med. Chem.</i> , 33(3): 978-985, 1990,						
		"Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV."						
100	55	Matsumoto et al., The Journal of Immunology, 131(6): 2762-2766, 1983,						
gre	<u> </u>	"Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycoformycin in Resting Lymphocytes."						
1	56	McCune et al., Cell, 53: 55-67, 1988,						
go	!	"Endoproteolytic Cleavage of gp160 is Required for the Activation of Human Immunodeficiency Virus."						
	57	Medina et al., Antimicrobial Agents and Chemotherapy, 36(5): 1127-1130, 1992,						
Tee 280	!	"Ganciclovir Antagonizes the Anti-Human-Immunodeficiency Virus Type I Activity of Zidovudine and Didanosine In Vitro."						
10-	58	Meyerhans et al., Journal of Virology, 68(1): 535-540, 1994,						
100	!	"Restriction and Enhancement of Human Immunodeficiency Virus Type 1 Replication by Modulation of Intracellular Deoxynucleosides Triphosphate Pools."						

EXAMINER DATE CONSIDERED 06/12/01

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. NIH061.1CP1C2

APPLICATION NO.

09/756,411

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT Lori et al.

FILING DATE herewith

GROUP Art Unit 1623

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
110	59	Meyerhans et al., VIII International Conference on AIDS/III STD World Congress, 2: A22-2118, July 1992,
pe		"The Intracellular Nucleotide Pool Effects HIV Replication."
Dea	60	New York Times, p. B19, November 24, 1995,
y	_	"Study Puts Risk of H.I.V. in Young U.S. Men at 1 in 92."
**	61	Pauwels-et-al., J. Virological-Methods, 20. 309-321, 1988,
**		"Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds."
1	62	Pegoraro et al., Experimental Cell Res., 68: 283-290, 1971,
MEC	_!	"Thymidine Kinase, Deoxycytidine Kinase and Deoxyctidylate Deaminase Activities in Phytohaemagglutinin Stimulated Human Lymphocytes."
91	63	Perno et al., J. of Exp. Medicine, 168: 1111-1125, 1988,
me	!	"Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-IIIBa-L) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2', 3'-Dideoxynucleosides."
Ω .	64	Popovic et al., Science, 224: 467-500, 1984,
gu	!	"Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-Aids."
mAG	65	Robinson, W., Fundamental Virology 2nd Edition, pp. 989-1021, Raven Press, New York, 1991,
y ce	<u> </u>	"Hepadnaviridae and Their Replication."
- **	-66	Reet-Bernstein, R.S., Genetic Engineering News, pp. 4-6, September-1, 1992,
		"AIDS is Moore than HIV: Part I."
<u>~</u> **-	67_	Root-Bernstein, R.S., Genetic-Engineering-News, pp. 4-5, September 15, 1992,
		"AIDS is Moore than HIV: Part II."
1.	68	Safrin et al., Journal of Medical Virology, Supplement 1, pp. 146-149, 1993,
Me	<u>'!</u>	"Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection."
	69	Schnittman et al., Science, 245: 305-308, 1989,
		"The Reservoir for HIV-1 in Human Peripheral Blood is a T Cell that Maitains Expression of CD4."
**	70	Schoofs, New York Times Magazine, pp. 32-35; June 21, 1998,
		"The Berlin Patient."
**	71-	Sigma-Chemical-Company, catalog, St. Louis, MO, pp. 321 and 341-342, 1992,
		"Biochemicals/Organic Compounds for Research and Diagnostic Reagents."
ale	72	Simonelli et al., European Aids Clinical Society, Book of Abstracts, September 1995,
yu		"Hydroxyurea as an Antiretroviral Drug in HIV Infected Patients: Clinical, Immunological and Virological Evaluation."

EXAMINER

L. E. Crane

DATE CONSIDERED

06/12/01

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

ATTY. DOCKET NO.
NIH061.1CP1C2

APPLICATION NO.
-- unknown-- 09/756,411

APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

Lori et al.

FILING DATE GROUP Art Unit 1623 - unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	_7 3	Snyder et al., DNA Repair and Its Inhibition Nucleic-Acids-Symposium-Series-No13, Collins et al., eds., Chapter 2, pp. 13-33, IRL Press, Oxford, England, 1984,						
		"The Accumulation of DNA Breaks Due to Incision: Comparative Studies with Various Inhibitors."						
**	74	Snyder et al., Mel. Pharmacel., 28(6): 574-580, 1985,						
		"Effectsof Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts."						
100	75	Stevenson et al., The EMBO Journal, 9(5): 1551-1560, 1990,						
pre	1	"HIV-1 Replication is Controlled at the Level of T Cell Activation and Proviral Integration."						
140	76	T'Ang et al., J. Med. Chem., 28: 1103-1106, 1985,						
me	1	"Optimization of the Schiff Bases of N-Hydroxy-N' aminoguanidine as Anticancer and Antiviral Agents."						
A.	77	Trono, D., J. of Virol., 66(8): 4893-4900, 1992,						
me.	!	"Partial Reverse Transcripts in Virions from Human Immunodeficiency and Murine Leukemia Viruses."						
The	78	Varmus et al., RNA Tumor Viruses, Molecular Biology of Tumor Viruses 2nd Ed., Chapter 5, pp. 369-512, 1982,						
gu	!	"Replication of Retroviruses."						
h.F.c	79	Vila et al., Lancet, 348(9021): 203-204, July 20, 1996,						
gra	ŕ	"1-year follow-up of the use of hydroxycarbamide and didanosine in HIV Infection."						
	80-	Vila-et-al .,-The-Lancet,- 350(9078):-635-636,-Aug ust 3 0,-1997,						
		"Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddl] and Hydroxycarbamide [aka Hydroxyureal]."						
Me	81 !	Villani, et al, "Pharmacokinetics of Hydroxyurea in Patents Infected with Human Immunodeficiency Virus Type I, Journal of Clinical Pharmacology, 36, 117-121 (1996)						
0.	82	Wilson et al. J. Clin. Invest., 64: 1475-1484, 1979,						
gre	!	"Purinogenic Immunodeficiency Disease - Differential Effects of Deoxyadenosine and Deoxyguanosine on DNA Synthesis in Human T Lymphoblasts."						
	83	-Yarchoan-et-al ., N. EnglJ. Medicine, 321(11):72 6-738, 1989,						
		"Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides."						
**	-84	Zack-et-al., <i>Gell</i> , 61: 213-222, 1990,						
		"HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure."						

** Duplicate of reference already of record on a PTO-892.

! Month of publication data is unavailable for this reference.

O:\DOC\$\NWV\NWV-3882.DOC 010501

					1	 		<u></u> .
EXAMINER	L.	E.	Crane	120	10-	DATE CONSIDERED	06/12/01	

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.